These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 24666728)

  • 41. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
    Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
    Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Non-coding RNAs in hepatitis C-induced hepatocellular carcinoma: dysregulation and implications for early detection, diagnosis and therapy.
    Hou W; Bonkovsky HL
    World J Gastroenterol; 2013 Nov; 19(44):7836-45. PubMed ID: 24307777
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Serum metabolic profiling study of hepatocellular carcinoma infected with hepatitis B or hepatitis C virus by using liquid chromatography-mass spectrometry.
    Zhou L; Ding L; Yin P; Lu X; Wang X; Niu J; Gao P; Xu G
    J Proteome Res; 2012 Nov; 11(11):5433-42. PubMed ID: 22946841
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B- and C-endemic area.
    Huang YC; Huang CF; Chang KC; Hung SF; Wang JH; Hung CH; Chen CH; Tseng PL; Kee KM; Yen YH; Tsai PS; Tsai CC; Lu SN
    J Gastroenterol Hepatol; 2011 Jan; 26(1):129-34. PubMed ID: 21175806
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Glutathione species and metabolomic prints in subjects with liver disease as biological markers for the detection of hepatocellular carcinoma.
    Sanabria JR; Kombu RS; Zhang GF; Sandlers Y; Ai J; Ibarra RA; Abbas R; Goyal K; Brunengraber H
    HPB (Oxford); 2016 Dec; 18(12):979-990. PubMed ID: 28340971
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Metabolic perturbations prior to hepatocellular carcinoma diagnosis: Findings from a prospective observational cohort study.
    Stepien M; Keski-Rahkonen P; Kiss A; Robinot N; Duarte-Salles T; Murphy N; Perlemuter G; Viallon V; Tjønneland A; Rostgaard-Hansen AL; Dahm CC; Overvad K; Boutron-Ruault MC; Mancini FR; Mahamat-Saleh Y; Aleksandrova K; Kaaks R; Kühn T; Trichopoulou A; Karakatsani A; Panico S; Tumino R; Palli D; Tagliabue G; Naccarati A; Vermeulen RCH; Bueno-de-Mesquita HB; Weiderpass E; Skeie G; Ramón Quirós J; Ardanaz E; Mokoroa O; Sala N; Sánchez MJ; Huerta JM; Winkvist A; Harlid S; Ohlsson B; Sjöberg K; Schmidt JA; Wareham N; Khaw KT; Ferrari P; Rothwell JA; Gunter M; Riboli E; Scalbert A; Jenab M
    Int J Cancer; 2021 Feb; 148(3):609-625. PubMed ID: 32734650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tissue and serum metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma.
    Han J; Qin WX; Li ZL; Xu AJ; Xing H; Wu H; Zhang H; Wang MD; Li C; Liang L; Quan B; Yan WT; Shen F; Wu MC; Yang T
    Clin Chim Acta; 2019 Jan; 488():68-75. PubMed ID: 30389456
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE.
    Ferrín G; Ranchal I; Llamoza C; Rodríguez-Perálvarez ML; Romero-Ruiz A; Aguilar-Melero P; López-Cillero P; Briceño J; Muntané J; Montero-Álvarez JL; De la Mata M
    Liver Int; 2014 Mar; 34(3):438-46. PubMed ID: 23944848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Untargeted metabolomics of blood plasma samples of patients with hepatocellular carcinoma.
    Böhmová A; Mikoška M; Syslová K; Šindelářová D; Hříbek P; Urbánek P; Setnička V
    J Pharm Biomed Anal; 2024 Sep; 248():116263. PubMed ID: 38852296
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system.
    Kanmura S; Uto H; Kusumoto K; Ishida Y; Hasuike S; Nagata K; Hayashi K; Ido A; Stuver SO; Tsubouchi H
    Hepatology; 2007 Apr; 45(4):948-56. PubMed ID: 17393466
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Urine metabolic fingerprinting using LC-MS and GC-MS reveals metabolite changes in prostate cancer: A pilot study.
    Struck-Lewicka W; Kordalewska M; Bujak R; Yumba Mpanga A; Markuszewski M; Jacyna J; Matuszewski M; Kaliszan R; Markuszewski MJ
    J Pharm Biomed Anal; 2015; 111():351-61. PubMed ID: 25684700
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabolomic study of the intervention effects of Shuihonghuazi Formula, a Traditional Chinese Medicinal formulae, on hepatocellular carcinoma (HCC) rats using performance HPLC/ESI-TOF-MS.
    Bao Y; Wang S; Yang X; Li T; Xia Y; Meng X
    J Ethnopharmacol; 2017 Feb; 198():468-478. PubMed ID: 28108381
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
    Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System.
    Tayob N; Richardson P; White DL; Yu X; Davila JA; Kanwal F; Feng Z; El-Serag HB
    BMC Med Res Methodol; 2018 Jan; 18(1):1. PubMed ID: 29301497
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Breast cancer detection using targeted plasma metabolomics.
    Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry.
    Chen S; Kong H; Lu X; Li Y; Yin P; Zeng Z; Xu G
    Anal Chem; 2013 Sep; 85(17):8326-33. PubMed ID: 23889541
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatocellular carcinoma and its early detection by AFP testing in Mongolia.
    Oyunsuren T; Sanduijav R; Davaadorj D; Nansalmaa D
    Asian Pac J Cancer Prev; 2006; 7(3):460-2. PubMed ID: 17059345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A panel of molecular markers in hepatitis C virus-related hepatocellular carcinoma.
    Elgendy SM; Hessien M; Elsherbiny MM; Abd El-Salam IM; El-Attar IA; El-Asser Ael-B
    J Egypt Natl Canc Inst; 2005 Dec; 17(4):270-8. PubMed ID: 17102821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Integrated plasma metabolomics and lipidomics profiling highlights distinctive signature of hepatocellular carcinoma in HCV patients.
    Caponigro V; Tornesello AL; Merciai F; La Gioia D; Salviati E; Basilicata MG; Musella S; Izzo F; Megna AS; Buonaguro L; Sommella E; Buonaguro FM; Tornesello ML; Campiglia P
    J Transl Med; 2023 Dec; 21(1):918. PubMed ID: 38110968
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evaluation of miR-331-3p and miR-23b-3p as serum biomarkers for hepatitis c virus-related hepatocellular carcinoma at early stage.
    Sun Q; Li J; Jin B; Wang T; Gu J
    Clin Res Hepatol Gastroenterol; 2020 Feb; 44(1):21-28. PubMed ID: 31053500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.